LLY

916.68

-3.69%↓

JNJ

238.73

-0.98%↓

ABBV

211.43

-5.07%↓

NVS

151.27

-2.46%↓

AZN

189.28

-1.76%↓

LLY

916.68

-3.69%↓

JNJ

238.73

-0.98%↓

ABBV

211.43

-5.07%↓

NVS

151.27

-2.46%↓

AZN

189.28

-1.76%↓

LLY

916.68

-3.69%↓

JNJ

238.73

-0.98%↓

ABBV

211.43

-5.07%↓

NVS

151.27

-2.46%↓

AZN

189.28

-1.76%↓

LLY

916.68

-3.69%↓

JNJ

238.73

-0.98%↓

ABBV

211.43

-5.07%↓

NVS

151.27

-2.46%↓

AZN

189.28

-1.76%↓

LLY

916.68

-3.69%↓

JNJ

238.73

-0.98%↓

ABBV

211.43

-5.07%↓

NVS

151.27

-2.46%↓

AZN

189.28

-1.76%↓

Search

United Therapeutics Corp

Open

SectorGezondheidszorg

526.49 -1.45

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

521.36

Max

540.84

Belangrijke statistieken

By Trading Economics

Inkomsten

26M

364M

Verkoop

-9.3M

790M

K/W

Sectorgemiddelde

19.192

61.417

Winstmarge

46.102

Werknemers

1,400

EBITDA

61M

524M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+1.11% upside

Dividenden

By Dow Jones

Volgende Winsten

29 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2B

23B

Vorige openingsprijs

527.94

Vorige sluitingsprijs

526.49

Nieuwssentiment

By Acuity

50%

50%

156 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

United Therapeutics Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mrt 2026, 22:42 UTC

Winsten

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mrt 2026, 21:40 UTC

Winsten

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mrt 2026, 23:56 UTC

Marktinformatie

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mrt 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mrt 2026, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 mrt 2026, 23:42 UTC

Marktinformatie

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mrt 2026, 23:38 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mrt 2026, 23:24 UTC

Marktinformatie

Global Energy Roundup: Market Talk

17 mrt 2026, 23:24 UTC

Marktinformatie

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mrt 2026, 22:22 UTC

Marktinformatie

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mrt 2026, 22:20 UTC

Winsten

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mrt 2026, 22:20 UTC

Winsten

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mrt 2026, 22:07 UTC

Winsten

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mrt 2026, 22:05 UTC

Winsten

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mrt 2026, 22:04 UTC

Winsten

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mrt 2026, 22:03 UTC

Winsten

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mrt 2026, 21:26 UTC

Winsten

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mrt 2026, 21:09 UTC

Winsten

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mrt 2026, 21:08 UTC

Winsten

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mrt 2026, 21:08 UTC

Winsten

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mrt 2026, 21:07 UTC

Winsten

Couche-Tard 3Q EPS 82c >ATD.T

17 mrt 2026, 21:06 UTC

Winsten

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q EPS 82c >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Net $757.2M >ATD.T

17 mrt 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Energy & Utilities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

United Therapeutics Corp Prognose

Koersdoel

By TipRanks

1.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 546 USD  1.11%

Hoogste 705 USD

Laagste 35 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor United Therapeutics Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technische score

By Trading Central

292.345 / 309.245Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

156 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat